Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Long-term survival following the development of heart failure in an elderly hypertensive population|
Wing Chair, L.
Shaw deceased, J.
|Citation:||Cardiovascular Therapeutics, 2017; 35(6):e12303|
|Berhe W. Sahle, Alice J. Owen, Lindon M.H. Wing, Lawrence J. Beilin Henry Krum, Christopher M. Reid on behalf of the Second Australian National Blood Pressure Study Management Committee|
|Abstract:||Background: Available data on the prognosis of heart failure (HF) patients are predominantly limited to patients diagnosed at time of hospitalization. Aims: To describe the long-term survival of incident HF patients and identify clinical characteristics associated with mortality. Methods: The Second Australian National Blood Pressure Study (ANBP2) randomized 6083 hypertensive subjects aged 65-84 years to angiotensin-converting enzyme (ACE) inhibitor or thiazide diuretic-based therapy and followed them for a median of 4.1 years. One hundred forty- five participants who developed HF and 5938 who re-mained free from HF during the trial period were followed for a median of 6.7 years during a posttrial follow- up. Results: Three quarters, 110 (76%) of HF patients had died at the end of the follow- up. The five- and ten- year survival rates following HF diagnosis during the trial period were 37% and 15%, respectively, in men, compared with 60% and 33%, respectively, in women. In non-heart failure participants, the five- and ten- year survival rates, following enrollment into the study, were 92% and 76%, respectively. Mortality following HF diagnosis increased with advancing age (HR = 1.09, 95% CI: 1.04- 1.33). In addition, male gender and preexisting diabetes were predictive of mortality, while ACE inhibitor-based therapy for the initial trial was associated with 39% decrease (HR = 0.61, 95% CI: 0.41- 0.91) in mortality compared with a thiazide diuretic–based regimen. Conclusions: Long- term survival in elderly HF patients is poor, especially in men. Mortality in HF patients increased progressively with advancing age, while allocation to the ACE inhibitor-based regimen for the initial trial significantly improved HF outcome.|
|Keywords:||Elderly; epidemiology; heart failure; hypertension; survival; treated|
|Rights:||© 2017 John Wiley & Sons Ltd.|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.